Benefits of early intensive glucose control in preventing diabetes-related complications were sustained for up to 10 years
R R Holman
Dr R R Holman, Churchill Hospital, Oxford, UK; rury.holman@dtu.ox.ac.uk
QUESTION
In patients with type 2 diabetes, do the benefits of early intensive glucose control in preventing diabetes-related complications continue after the intervention is stopped?
METHODS
Design:
randomised controlled trial (UK Prospective Diabetes Study [UKPDS]).
Allocation:
{concealed}.*
Blinding:
blinded (outcome adjudication committee).
Follow-up period:
median 9 years after the end of the trial, 17 years total.
Setting:
23 centres in the UK.
Patients:
4209 patients 25–65 years of age {mean age 53 y, 60% men}* who had newly diagnosed type 2 diabetes and fasting plasma glucose concentrations >6.0 mmol/l (108 mg/dl) and <15.0 mmol/l (270 mg/dl) after 3 months of dietary therapy. Exclusion criteria included ketonuria, elevated serum creatinine, recent myocardial infarction, angina, …
